A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Pro... Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamet... Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s...STOCK Quote
NASDAQ: AERI
$12.73USD
Aug 14, 3:20 PM ET
VOLUME
355,245
DAY LOW/HIGH
$12.24/$12.87
52 - WEEK LOW/HIGH
$10.80/$26.26
